FSD-PEA

FSD-PEA is an oral **ultra-micronized palmitoylethanolamide** formulation being developed by **FSD Pharma** through **FSD BioSciences** as a small-molecule anti-inflammatory drug for inflammatory and pain-related disorders. The product is described as a proprietary 600 mg oral tablet with particle sizes of approximately 0.6 to 10 microns and has been positioned for indications including chronic pain associated with idiopathic mast cell activation syndrome, COVID-19-related inflammation, osteoarthritis, and other inflammatory disorders. Its proposed mechanism involves modulation of the endocannabinoid-related signaling network, including cannabinoid receptors, G-protein-coupled receptor 55, and peroxisome proliferator-activated receptor alpha, consistent with anti-inflammatory and analgesic effects of palmitoylethanolamide-based therapies. The program reportedly completed Phase 1 safety testing in Australia and advanced into Phase 2 development, and FSD Pharma obtained worldwide rights outside Italy and Spain through its acquisition of Prismic Pharmaceuticals.

Other names

ultra-micronized palmitoylethanolamide